[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse MBD1

Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus matrix Nucleus speckle. Chromosome. Note=Colocalizes with the Ten-1 ICD form of TENM1 in foci associated with the nuclear matrix (By similarity). Nuclear, in a punctate pattern. Associated with euchromatic regions of the chromosomes, with pericentromeric regions on chromosome 1 and with telomeric regions from several chromosomes.
Domain PF01429 Methyl-CpG binding domain
PF02008 CXXC zinc finger domain
Function

Transcriptional repressor that binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binding is abolished by the presence of 7-mG that is produced by DNA damage by methylmethanesulfonate (MMS). Acts as transcriptional repressor and plays a role in gene silencing by recruiting AFT7IP, which in turn recruits factors such as the histone methyltransferase SETDB1. Probably forms a complex with SETDB1 and ATF7IP that represses transcription and couples DNA methylation and histone 'Lys-9' trimethylation. Isoform 1 and isoform 2 can also repress transcription from unmethylated promoters.

> Gene Ontology
 
Biological Process GO:0006304 DNA modification
GO:0006305 DNA alkylation
GO:0006306 DNA methylation
GO:0006342 chromatin silencing
GO:0006346 methylation-dependent chromatin silencing
GO:0007507 heart development
GO:0007568 aging
GO:0009991 response to extracellular stimulus
GO:0010001 glial cell differentiation
GO:0010721 negative regulation of cell development
GO:0014013 regulation of gliogenesis
GO:0014014 negative regulation of gliogenesis
GO:0016458 gene silencing
GO:0031667 response to nutrient levels
GO:0032259 methylation
GO:0032355 response to estradiol
GO:0040029 regulation of gene expression, epigenetic
GO:0042063 gliogenesis
GO:0042220 response to cocaine
GO:0043279 response to alkaloid
GO:0043414 macromolecule methylation
GO:0044030 regulation of DNA methylation
GO:0044728 DNA methylation or demethylation
GO:0045685 regulation of glial cell differentiation
GO:0045686 negative regulation of glial cell differentiation
GO:0045814 negative regulation of gene expression, epigenetic
GO:0048708 astrocyte differentiation
GO:0048710 regulation of astrocyte differentiation
GO:0048712 negative regulation of astrocyte differentiation
GO:0050768 negative regulation of neurogenesis
GO:0051052 regulation of DNA metabolic process
GO:0051961 negative regulation of nervous system development
Molecular Function GO:0003682 chromatin binding
GO:0008327 methyl-CpG binding
GO:0010385 double-stranded methylated DNA binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0016363 nuclear matrix
GO:0016604 nuclear body
GO:0016607 nuclear speck
GO:0034399 nuclear periphery
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MBD1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MBD1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MBD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0190.912
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0150.994
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0430.976
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3870.318
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5650.801
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1660.955
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1740.624
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2490.872
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0730.967
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3180.822
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.860.674
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1090.114
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MBD1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.81.713.10.032
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MBD1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MBD1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MBD1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MBD1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MBD1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MBD1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMBD1
Namemethyl-CpG binding domain protein 1
Aliases CXXC3; RFT; CXXC-type zinc finger protein 3; methyl-CpG binding domain protein 1 isoform PCM1; protein conta ......
Chromosomal Location18q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MBD1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.